Loading…
Loading…
Embecta (NASDAQ: EMBC - Get Free Report) and Rockwell Medical (NASDAQ: RMTI - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Profitability This table compares Embecta and Rockwell Medical's
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC).
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC).
In September, embecta will participate in the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize.
New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. NEW YORK, Aug. 18, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.